Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Sarcoma 1Recurrent respiratory papillomatosis 1Papilloma 1Neoplasm Metastasis 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

pembrolizumab 6Sunitinib 5Bevacizumab 4Sorafenib 3Radiotherapy 3Radiosurgery 3Nivolumab 3Magnetic Resonance Spectroscopy 3Interleukin-2 3Cyclophosphamide 3Axitinib 3tivozanib 2fludarabine phosphate 2durvalumab 2avelumab 2atezolizumab 2Peripheral Blood Stem Cell Transplantation 2Optical Imaging 2Nephrectomy 2Gene Expression Profiling 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2tremelimumab 1temsirolimus 1siltuximab 1sargramostim 1pazopanib 1pamiparib 1milademetan 1lenvatinib 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Carcinoma, Renal Cell × Propranolol × Clear all
NCT03323710 2019-01-09

Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma

Military Institute od Medicine National Research Institute

Phase 2 Withdrawn
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡